The FDA’s reservations about the battery system and its innovative transdermal charging capabilities centre on the device’s failure rate. According to Reuters, the FDA is looking for assurances that the battery is “extremely unlikely to fail,” because a ruptured pack’s release of electrical current or heat energy might destroy the surrounding tissue.
